Form 4: Ionis Pharma EVP Granted 19,350 Stock Options

Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals, received a grant of 19,350 non-qualified stock options with a multi-year vesting schedule.

Summary

• Brian Birchler, Executive Vice President of Corporate and Development Operations at Ionis Pharmaceuticals, Inc. (IONS), was granted non-qualified stock options.
• The transaction occurred on January 2, 2026.
• A total of 19,350 derivative securities (stock options) were acquired.
• The exercise price for these options is $79.67 per share.
• The options have an expiration date of January 1, 2036.
• The vesting schedule begins with 25% of the shares becoming exercisable on January 2, 2027.
• The remaining shares will vest and become exercisable in 36 equal monthly installments over the subsequent three years.
• Following this transaction, Brian Birchler beneficially owns 19,350 derivative securities directly.

Sentiment

Score: 6

Explanation: This is a routine Form 4 filing reporting an executive compensation event (stock option grant). It is generally neutral but can be seen as slightly positive as it aligns executive interests with shareholders over the long term.

Positives

• The grant of stock options aligns the executive's long-term financial interests with those of the shareholders, incentivizing performance.
• The multi-year vesting schedule encourages long-term commitment and retention of key management personnel.

Negatives

• No direct negatives are identified in this routine insider transaction report.

Risks

• The value of the stock options is subject to the future performance of Ionis Pharmaceuticals' stock price, which carries inherent market risk.
• If the stock price does not exceed the exercise price of $79.67, the options may expire worthless.

Future Outlook

The multi-year vesting schedule for the stock options indicates a long-term incentive structure for the executive, aligning their future performance with the company's stock appreciation over the next four years.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to compensate executives, attract talent, and align management incentives with shareholder value creation. Such equity-based compensation is a standard component of executive pay packages, particularly in growth-oriented sectors like biotech where long-term value creation is paramount.

Stakeholder Impact

• Shareholders: The grant aims to align executive incentives with shareholder value creation, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: This specific filing relates to a single executive's compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• Continued vesting of the remaining 75% of stock options in 36 equal monthly installments over three years following January 2, 2027.
• Potential exercise of vested stock options by Brian Birchler prior to the expiration date of January 1, 2036.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, stock options, executive compensation, Form 4, insider transaction, Brian Birchler, equity incentive plan, biotechnology